<DOC>
	<DOC>NCT00069108</DOC>
	<brief_summary>This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal cancer. Patients will be randomized to receive either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patients &gt;=18 years of age; metastatic colorectal cancer; &gt;=1 target lesion; failed firstline chemotherapy with 5fluorouracil and irinotecan. previous treatment with oxaliplatin; progressive or recurrent disease during or within 6 months of completion of firstline chemotherapy; &gt;=1 previous chemotherapeutic agent or systemic anticancer regimen for metastatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>